The U.S. Food and Drug Administration approved 27 drugs in December 2025—the month’s high—bringing the annual total to 226 approvals. That places 2025 just below 2024’s 228 approvals but well above most years in the prior decade. The December surge underscores sustained regulatory throughput amid evolving review frameworks and increasing use of expedited pathways.